Open AccessOlanzapine induced neuroleptic malignant syndrome
Author(s) -
Bichitra Nanda Patra,
Shubham Khandelwal,
Mamta Sood
Publication year - 2013
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.106448
Subject(s) - neuroleptic malignant syndrome , bromocriptine , olanzapine , antipsychotic , medicine , atypical antipsychotic , pediatrics , psychiatry , anesthesia , schizophrenia (object oriented programming) , prolactin , hormone
An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome.